Stocktoria

AGENUS INC AGEN

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2000-02-04 · LEI

AGENUS INC financials (annual)

Revenue
$22.6M $42.9M $36.8M $150.0M $88.2M $295.7M $98.0M $156.3M $103.5M $114.2M 2016201720182019202020212022202320242025
Net income
-$127.0M -$120.7M 2016201720182019202020212022202320242025
Free cash flow
-$92.5M -$97.3M -$134.7M -$23.3M -$142.6M -$23.7M -$228.4M -$234.2M -$158.9M -$77.2M 2016201720182019202020212022202320242025

Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$114.2M$103.5M$156.3M$98.0M$295.7M$88.2M$150.0M$36.8M$42.9M$22.6M
R&D expense$79.3M$155.5M$234.6M$186.7M$178.6M$142.6M$168.3M$124.6M$116.1M$95.0M
Operating income-$20.2M-$120.5M-$159.5M-$179.4M$25.7M-$117.2M-$70.1M-$123.8M-$103.8M-$107.5M
Income tax$0$0$0$0$0$0$0$0$0$0
Net income-$120.7M-$127.0M
EPS (diluted)$0.00$-10.59$-13.75$-15.64$-0.11$-1.05
Operating cash flow-$77.2M-$158.3M-$224.2M-$175.4M$10.1M-$139.1M-$18.7M-$131.1M-$94.2M-$80.0M
Free cash flow-$77.2M-$158.9M-$234.2M-$228.4M-$23.7M-$142.6M-$23.3M-$134.7M-$97.3M-$92.5M
Cash & equivalents$3.0M$40.4M$76.1M$178.7M$291.9M$99.9M$61.8M$53.1M$60.2M$71.4M
Inventory$0$55,000$79,491$88,200
Total assets$226.8M$226.3M$313.9M$413.6M$466.0M$214.5M$155.3M$136.4M$138.4M$157.0M
Shareholders' equity-$277.9M-$326.4M-$160.3M-$61.3M$47.9M-$211.5M-$231.3M-$174.5M-$75.8M-$39.1M

Growth · year-over-year · Revenue CAGR 19.7%

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue growth+10.4%-33.8%+59.5%-66.8%+235.3%-41.2%+307.9%-14.2%+89.9%-9.0%

Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.